Key clinical point: In mild to moderate asthma, as-needed is superior to maintenance inhaled budesonide for preventing severe exacerbations.
Major finding: The per-patient rate of severe exacerbations (0.119 vs. 0.172) was significantly lower (HR 0.69; P = .049) in the as-needed group.
Study details: Multicenter, randomized, open-label trial.
Disclosures: Dr. Hardy reports no potential conflicts of interest.
REPORTING FROM ERS 2019